, Volume 27, Issue 3, pp 215–219 | Cite as

Profile and prevalence of HBV among HIV affected individuals attending the largest public HIV care center in India

  • Suneeta Koli
  • C. P. Girish Kumar
  • V. Selvaraj
  • R. Prabu
  • C. Chandrasekar
  • A. S. Valan
  • J. Suria Kumar
  • K. Raja
Original Article


A large number of people living with HIV/AIDS residing in HBV endemic regions such as in India are highly susceptible to acquire co-infections like HBV but also transmit them to other due to their high risk behaviours. The present study aimed to estimate HBV prevalence and distribution of various HBV serological markers among HIV infected individuals. This cross sectional survey covered HIV infected individuals attending the largest HIV care center in India. Socio-demographic details and blood samples to screen for HBV seromarkers using commercial ELISA kits were collected. Among 1160 HIV infected patients, prevalence of HBcAb, HBsAb, HBsAg and HBeAg was 66, 29.4, 16.6 and 5.8 % respectively. Overall, 28.9 % individuals had no evidence of any of the four markers, indicating lack of previous exposure and future risk of acquiring HBV infection. Presence of anti-HBsAg in a mere 0.9 % of individuals reflected low levels HBV vaccine conferred immunity which could be due to poor HBV vaccine coverage in this high risk population. With high prevalence and evidence of exposure to HBV as well as considering the growing literature on increase in hepatic complications in HIV-HBV co-infected individuals, the need for mandatory HBV screening of all HIV infected individuals cannot be over-emphasised. The policy makers and HIV programme managers must consider HBV vaccination for newly detected HBV naive HIV infected individuals and also focus on creating public awareness on HBV and HIV prevention.


HIV HBV co-infection Seromarkers Prevalence Chennai India 



The authors thank Dr. Sanjay Mehendale, Director, National Institute of Epidemiology, Chennai for his constant support and guidance throughout the study and for the valuable suggestions towards the improvement of the manuscript. This study was supported by the post-doctoral fellowship grant awarded to SK from Indian Council of Medical Research (ICMR), Government of India. The authors thank the study participants; the technical staff and medical officers of the GHTM for their kind support. Special note of thanks to Mr. D. Murugan (NIE) for valuable support in data collection and Dr. Abbas, Mr. Gajendran and Mr. S. Saravanan for operational support at GHTM.


  1. 1.
    Sarin SK, Kumar M. Epidemiology, screening, and natural history of chronic hepatitis B infection. In: Shetty K, Wung GY, editors. From clinical gastroenterology: chronic viral hepatitis. New York City: Humana Press, LLC; 2009.Google Scholar
  2. 2.
    Puri P. Tackling the hepatitis B disease burden in India. J Clin Exp Hepatol. 2014;4(4):312–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Benhamou Y. Hepatitis B in the HIV-co-infected patient. JAIDS. 2007;45(Suppl 2):S57–67.PubMedGoogle Scholar
  4. 4.
    Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol. 2006;44:S25–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Tankhiwale SS, Khadase RK, Jalgoankar SV. Seroprevalence of anti-HCV and hepatitis B surface antigen in HIV infected patients. Indian J Med Microbiol. 2003;21(4):268–70.PubMedGoogle Scholar
  6. 6.
    Chandra N, Joshi N, Raju YS, Kumar A, Teja VD. Hepatitis B and/or C co-infection in HIV infected patients: a study in a tertiary care centre from South India. Indian J Med Res. 2013;138(6):950–4.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Padmapriyadarsini C, Chandrabose J, Victor L, Hanna LE, Arunkumar N, Swaminathan S. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J Postgrad Med. 2006;52:92–6.PubMedGoogle Scholar
  8. 8.
    Saravanan S, Velu V, Kumarasamy N, Nandakumar S, Murugavel KG, Balakrishnan P, Suniti S, Thyagarajan SP. Co-infection of hepatitis B and hepatitis C virus in HIV infected patients in South India. World J Gastroenterol. 2007;13:5015–20.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pal A, Panigrahi R, Biswas A, Datta S, Sarkar N, Guha SK, Saha B, Banerjee A, Chakrabarti S, Chakravarty R. Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients. Virology. 2013;436:134–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, Sankalé JL, Ekong E, Murphy R, Kanki P, Thio CL. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009;49(8):1268–73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R, Agarwal K, Sabin C, Deacon-Adams C, BHIVA Viral Hepatitis Working Group. British HIV association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med. 2010;11:1–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45:1221–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79:1464–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Gupta S, Singh S. Occult hepatitis B Virus infection in ART-naïve HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis. 2010;10:53.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1000 patients. JAMA. 1979;241:1239–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Ungo JR, Jone D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Anti-tuberculosis drug induced hepatotoxicity:the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Care Med. 1998;157:1871–6.CrossRefGoogle Scholar
  17. 17.
    Chaudhry AA, Sulkowski MS, Chander G, Moore RD. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009;10:133–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.CrossRefPubMedGoogle Scholar

Copyright information

© Indian Virological Society 2016

Authors and Affiliations

  • Suneeta Koli
    • 1
  • C. P. Girish Kumar
    • 1
  • V. Selvaraj
    • 1
  • R. Prabu
    • 1
  • C. Chandrasekar
    • 2
  • A. S. Valan
    • 2
  • J. Suria Kumar
    • 2
  • K. Raja
    • 2
  1. 1.National Institute of Epidemiology (ICMR)ChennaiIndia
  2. 2.Government Hospital of Thoracic MedicineTambaram Sanatorium, ChennaiIndia

Personalised recommendations